Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Dri Healthcare Trust T.DHT.UN

Alternate Symbol(s):  DHTRF

DRI Healthcare Trust is a Canada-based company engaged in global pharmaceutical royalty monetization. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It acquires more than 25 royalties on 20-plus drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Ilaris, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Simponi, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, sebetralstat, and others. Its therapeutic areas include hematology, ophthalmology, influenza, endocrinology, dermatology, oncology, neurology, immunology, lysosomal storage disorder, hereditary angioedema, and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; and others.


TSX:DHT.UN - Post by User

User Avatar Image
(70)
•••
  • SONOFFERGUSX
Comment by SONOFFERGUSon Apr 22, 2025 3:35pm
60 Views
Post# 36547205

RE:RE:RE:T3 Error Update

RE:RE:RE:T3 Error UpdateHey.

I'm glad that it's only a few dollars given how terribly DHT has performed since the fraud.

I continue to think that (1) Kalvista's stock price and words from its CEO are telling us that the FDA approval June 17th is a virtual certainty, and (2) DHT mgmt is going to announce the management internalization and buyback right after that approval.  Obviously, mgmt benefits from the lowest possible unit price when deferred units are handed out on the reorg so is overjoyed with the current state of affairs.

I note that Goldman has been an active seller and that the DRI CEO is a GS alumnus.  I'm not saying that something nefarious is going on, but I'm not saying there isn't.  Again today, my pharma screen is big green except for one name.  It is incredibly frustrating.

On taxes, I was in that business decades ago, so I'll get wonky for a second  The reason that brokers produce their own slips for this situation is specifically because the amount you received in your CAD account is different from what DHT paid in USD, and DHT has no way of knowing that amount. You are conflating consistency wrt conversion to CAD of amounts received in foreign currency in a foreign currency account (i.e., using an annual average vs spot at each receipt)  with receipt of such amounts in your CAD account -- for which no conversion is required as you got what you got. 

Good luck to all of us!


<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities